Gang Li

Gang Li


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
JCJunlan Chuan
Junlan Chuan
LLLianqiao Liu
Lianqiao Liu
YFYumei Feng
Yumei Feng
MWMengdan Wang
Mengdan Wang
GLGang Li
Gang Li
JCJunlan Chuan
Junlan Chuan
Introduction: As demonstrated in pivotal clinical trials, brolucizumab can be used to treat neovascular age-related macular degeneration (nAMD) because it antagonizes vascular endothelial growth factor (VEGF) in the vitreous. However, brolucizumab may cause retinal vasculitis obliterans in the presence of inflammation in the eyes. In the present study, a meta-analysis of randomized controlled trials (RCTs) was conducted to evaluate the efficacy and safety of brolucizumab.Methods:ClinicTrail.gov., Embase, Cochrane Library, and PubMed were retrieved from inception until 31 December 2021 for RCTs assessing the efficacy and safety of brolucizumab. Changes in best corrected visual acuity (BCVA) and central sub-field thickness (CSFT) and incidence of adverse events, serious adverse events, and serious ocular adverse events were extracted from eligible RCTs. A meta-analysis was performed using RevMan 5.4.1.Results: A total of six RCTs with 3,574 participants were finally involved in this meta-analysis. The changes of best corrected visual acuity (BCVA) showed no statistically significant difference between the brolucizumab-treated group and aflibercept-treated group. Brolucizumab induced higher central sub-field thickness (CSFT) reduction than the control agent (aflibercept). The incidence of adverse events was similar between the brolucizumab group and control group (OR 0.63, 95% CI 0.37 to 1.08, p = 0.09), and brolucizumab caused fewer serious adverse events (OR 0.78, 95% CI 0.63 to 0.95, p = 0.01). However, brolucizumab could lead to more serious ocular adverse events than Lucentis and aflibercept (OR 2.15, 95% CI 1.11 to 4.16, p = 0.02).Conclusion: Brolucizumab was non-inferior to other anti-VEGF agents in improving BCVA and decreasing CSFT. But it caused more serious ocular adverse events which is worthy of special attention by ophthalmologists.

14 October 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
CHChangli He
Changli He
YWYin Wang
Yin Wang
HZHan Zhang
Han Zhang
SLSitian Li
Sitian Li
FKFengjiao Kang
Fengjiao Kang
YBYuan Bian
Yuan Bian
Background: Patients diagnosed with malignant tumors exhibit a markedly elevated risk of venous thromboembolism (VTE), which has a negative impact on their prognosis. Currently, there is no reliable predictive model specifically for thrombosis risk in lymphoma patients. This study aims to develop and validate a machine learning model leveraging real-world data, offering a dependable risk assessment tool for the early identification of VTE in lymphoma patients.Methods: We retrospectively analyzed 605 hospitalized patients with lymphoma between January 2019 and June 2024. Candidate predictors included demographic characteristics, comorbidities and medical history, tumor-related factors, treatment-related factors, and laboratory parameters. The primary endpoint was the occurrence of VTE within 6 months after hospitalization for confirmed lymphoma. Model development incorporated three imputation methods, three sampling strategies, three feature selection approaches, and nine machine learning algorithms. Predictive performance was compared across all models.Results: Combining different imputation, sampling, and feature selection strategies yielded 27 datasets, which were trained across nine algorithms to generate 243 models. The optimal model—Simp-SMOTE_rf_GBM, constructed using random forest imputation, SMOTE oversampling, and gradient boosting machine—achieved the highest predictive performance (AUC = 0.954). SHAP-based model interpretation identified nine key predictors ranked by importance: anticoagulant use, D-dimer, lactate dehydrogenase, central venous catheterization, carcinoembryonic antigen (CEA), Eastern Cooperative Oncology Group (ECOG) score, serum total protein (TP), total cholesterol (TC), and infectious disease.Conclusion: This study established and validated a machine learning model for predicting VTE risk in lymphoma patients, with the optimal model demonstrating excellent discriminatory ability (AUC = 0.954). The model provides evidence to guide the timing and strategy of anticoagulation, supporting early VTE screening and risk stratification in clinical practice. Its implementation has important implications for improving patient outcomes and advancing public health.

10 March 2026 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
LHLizhu Han
Lizhu Han
SLSitian Li
Sitian Li
JLJianting Liao
Jianting Liao
QYQinan Yin
Qinan Yin
CHChangli He
Changli He
YBYuan Bian
Yuan Bian
Background: Endothelin receptor antagonists (ERAs), including bosentan, ambrisentan, and macitentan, are recognized as first-line treatments for pulmonary arterial hypertension (PAH). Although their therapeutic efficacy is well established, variations in receptor selectivity and metabolic pathways may lead to distinct adverse drug event (ADE) profiles. Nonetheless, large-scale, real-world comparative safety data remain limited. As part of routine pharmacovigilance activities, we analyzed data from the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) to identify disproportionate reporting signals. Objective: This study leveraged data from FAERS to identify and compare potential ADEs associated with bosentan, ambrisentan, and macitentan, thereby facilitating safer and more informed clinical decision-making in pharmacotherapy. Methods: A disproportionality analysis of individual case safety reports (ICSRs) from the FAERS was performed for the period spanning Q1 2004 to Q2 2025. The classification of ADEs was conducted utilizing the Medical Dictionary for Regulatory Activities (MedDRA®) terminology. Signal detection was executed employing four distinct algorithms: the Reporting Odds Ratio (ROR), the Proportional Reporting Ratio (PRR), the Bayesian Confidence Propagation Neural Network (BCPNN), and the Multi-item Gamma Poisson Shrinker (MGPS), all based on an observational and retrospective proportional imbalance analysis of the FAERS database. Additionally, a Time-to-Onset (TTO) analysis was conducted to evaluate the temporal distribution of ADEs. Results: A total of 35,112, 48,411, and 29,877 ADE reports were collected for bosentan, ambrisentan, and macitentan, respectively. The majority of reports originated from female patients, with a male-to-female ratio of 1:2.91, aged between 18 and 65 years. Ambrisentan was disproportionally more frequently reported the highest incidence of ADEs, accounting for 42.69% of cases. Significant ADE signals were identified in the hepatobiliary, hematologic, cardiovascular, respiratory, and fluid retention-related categories. The observed ADEs predominantly comprised peripheral edema, dyspnea, liver function abnormalities, and anemia, consistent with the documented drug labeling. It is crucial that novel signals were identified, including jaw pain, pulmonary thrombosis, gout, decreased blood potassium, and hypotension. TTO analysis revealed that the majority of ADEs occurred within the first year of treatment. Conclusion: This study corroborated the established ADEs associated with ERAs and identified novel ADE signals, thereby providing new insights into their safety profile. The findings emphasize the importance of comprehensive monitoring of hepatic function, blood pressure, renal function, and electrolyte levels during ERA treatment. These results provide valuable insights for clinicians aiming to optimize ERA utilization, minimize associated risks, and improve patient outcomes. Future research should focus on elucidating the underlying mechanisms of these ADEs to further enhance the safety and efficacy of ERA therapies.

2 February 2026 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
HLHuan Liu
Huan Liu
WLWenwen Lin
Wenwen Lin
HTHai Tian
Hai Tian
GLGang Li
Gang Li
XDXiyu Dang
Xiyu Dang
The therapeutic vaccine landscape for non-small cell lung cancer (NSCLC) has evolved substantially over the past three decades, yet systematic analysis of this progression remains limited. We conducted bibliometric analysis of NSCLC vaccine research using 765 publications spanning 1990-2025 from Web of Science and Scopus databases. Our temporal analysis revealed a marked paradigm shift from early investigations on single-antigen approaches (particularly MAGE-A3) and specific platforms such as BLP25 liposome vaccines toward combination strategies integrating immune checkpoint inhibitors (ICIs) and advanced RNA vaccine technologies. This reflects reorientation from standalone vaccine modalities to synergistic approaches combining vaccines with established therapeutics, including ICIs, targeted therapies, and antibody-drug conjugates. This bibliometric analysis provides the first systematic mapping of NSCLC vaccine research evolution, revealing a clear trajectory toward combination immunotherapy strategies and offering an evidence-based framework for identifying research priorities and informing future development directions in cancer vaccine research.

17 December 2024 in Wireless Personal Communications
Verified
Journal Article
Closed access
PDF file
JLJia Li
Jia Li
YGYugang Gu
Yugang Gu
YLYi Liang
Yi Liang
GLGang Li
Gang Li
YYYuchun Yang
Yuchun Yang